Investor Day 2016
Logotype for CVS Health Corporation

CVS Health (CVS) Investor Day 2016 summary

Event summary combining transcript, slides, and related documents.

Logotype for CVS Health Corporation

Investor Day 2016 summary

4 Nov, 2026

2016 performance

  • Adjusted EPS expected at $5.77-$5.83, up 11.75%-13%; net revenue growth expected at 16%-16.5%.

  • FY16 free cash flow expected at $6.8B-$7B, with $6.9B cited as an accomplishment.

  • Approximately $6B expected to be returned to shareholders through dividends and buybacks.

  • 2017 PBM selling season generated $7.8B in gross new business, with ~97% client retention; commercial client drug trend was 3.3% through September, net of rebates.

  • Specialty dispensed revenue forecast to grow ~19% in 2016; enterprise script and claim growth was ~19%, including Omnicare and Target pharmacies.

2017 outlook

  • Net revenue growth guidance of 4%-5.75%; adjusted EPS of $5.77-$5.93, a YoY change of (0.5%)-2.5%; GAAP diluted EPS of $5.02-$5.18.

  • Free cash flow guidance of $6B-$6.4B, down 7%-13% YoY; cash from operations of $7.7B-$8.6B.

  • PBM revenue growth expected at 8.5%-10.5% and operating profit growth at 6.5%-9.5%; retail/LTC revenue flat to down 1.5%, comp scripts flat to up 1%, and operating profit down 7%-9.5%.

  • Guidance reflects >40M lost prescriptions, slower Omnicare and Target accretion, and ongoing margin pressure; acquisitions expected to add $0.17 to EPS, below the originally anticipated pace.

  • Earnings growth expected to be significantly back-half weighted, reflecting calendar timing, generic launches, Medicare Part D and the streamlining initiative.

Long-term targets and cost efficiency

  • Steady-state targets: ~5% net revenue growth, ~6% operating profit growth and ~10% adjusted EPS growth; annual free cash flow target of $7B-$8B.

  • Multi-year streamlining targets $700M-$750M in annual savings by 2021 and $3B cumulative savings over five years; savings expected to exceed costs beginning in 2018.

  • Plan includes closing ~70 stores, consolidating back-office shared services and redistributing prescription fulfillment work; closures carry a $265M estimated charge, largely in 2017.

  • Relocated shared-services activities achieved 15%-20% labor cost reductions; adjusted debt/EBITDA target remains ~2.7x, with debt reduction planned as maturities come due.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from CVS Health